Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study-

Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study- - Study for satisfaction and efficacy of dulaglutide

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024552

Enrollment

Registered

2016-11-01

Start date

2016-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Keeping daily GLP-1 receptor agonist Switching from daily GLP-1 receptor agonist to dulaglutide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who were 20-year-old or older at the time of obtaining informed consent 2)Patients whose HbA1c level is more than 6.0% and less than 9.0% at the time of obtaining informed consent 3)Patients who were taking GLP-1 receptor agonist more than three months 4)Patients who are able to understand the study and willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients who were taking weekly GLP-1 receptor agonist at the time of obtaining informed consent 2)Patients who have experienced severe diabetic ketosis, diabetic coma, or past history of pre-coma within six months 3)Patients with pregnancy or lactation 4)Patients who are taking systemic corticosteroid 5)Type 1 diabetes 6)Patients with severe infection, pre or post operation and severe trauma 7)Patients with severe liver dysfunction 8)Patients with severe renal dysfunction 9)Patients who are deemed to be unsuitable by the investigator

Design outcomes

Primary

Measure	Time frame
The score of Diabetes Treatment Satisfaction Questionnaire (DTSQ)	—

Secondary

Measure	Time frame
1)The score of Diabetes Therapy Related Quality of life (DTR-QOL) 2)Plasma glucose and HbA1c 3)Body weight and body mass index (BMI) 4)Blood test 5)The assessment of safety: frequency of hypoglycemia, digestive symptom, and so on	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Graduate School Division of Rheumatology, Endocrinology and Nephrology

hmiyoshi@med.hokudai.ac.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026